Fundraising Fox
Gut-Brain-Axis Therapeutics
Tempe, US · Founded 2022 · Delaware corporation · 1 known investors
Find your way into Gut-Brain-Axis Therapeutics
Sign up to see every warm intro you have to Gut-Brain-Axis Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gut-Brain-Axis Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
A biotech company developing Microbiota Transplant Therapy (MTT), a patented treatment that restructures the gut microbiome to improve symptoms of Autism Spectrum Disorder and Pitt-Hopkins Syndrome. Its therapies are in Phase 2b clinical trials, with FDA submissions and Phase 3 planned for 2026.
Founders & leadership
Gut-Brain-Axis Therapeutics was founded in 2022 by Rosa Krajalnik-Brown.
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.4M disclosed across 2 rounds · 2023–2025
▶$2MraisedNov 2025 · 22 investors · BiotechnologyRule 506(c)
▶$2MraisedNov 2025 · 22 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Alexander KhorutsDirector
- James B. AdamsExecutive Officer, Director
- Michael J. SadowskyDirector
- Rosa Krajmalnik-BrownDirector
- Offering amount
- $20M
- Amount sold
- $2M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06c
▶$1.4MraisedOct 2023 · 23 investors · BiotechnologyRule 506(c)
▶$1.4MraisedOct 2023 · 23 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Rosa Krajalnik-BrownDirector
- Michael J SadowskyDirector
- James B AdamsExecutive Officer, Director
- Alexander KhorusDirector
- Offering amount
- $8M
- Amount sold
- $1.4M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Gut-Brain-Axis Therapeutics do?
- A biotech company developing Microbiota Transplant Therapy (MTT), a patented treatment that restructures the gut microbiome to improve symptoms of Autism Spectrum Disorder and Pitt-Hopkins Syndrome. Its therapies are in Phase 2b clinical trials, with FDA submissions and Phase 3 planned for 2026.
- Who founded Gut-Brain-Axis Therapeutics?
- Gut-Brain-Axis Therapeutics was founded by Rosa Krajalnik-Brown in 2022.
- Who are Gut-Brain-Axis Therapeutics's investors?
- Gut-Brain-Axis Therapeutics's investors include Healthtech Capital.
- How much funding has Gut-Brain-Axis Therapeutics raised?
- Gut-Brain-Axis Therapeutics has disclosed $3.4M raised across 2 rounds.
- Where is Gut-Brain-Axis Therapeutics headquartered?
- Gut-Brain-Axis Therapeutics is headquartered in Tempe, US.